Q
Quiet Therapeutics
Targeted GAGomer nanoparticle platform for cancer therapies
About Quiet Therapeutics
Quiet Therapeutics was a biopharmaceutical company founded in 2010 by Professor Dan Peer and Professor Rimona Margalit, with its headquarters in Ness Ziona, Israel. The firm operated as a portfolio company of Pontifax and Arkin Holdings and was established within an incubator program supported by the Israeli Office of the Chief Scientist. The company's core focus was the development of a proprietary, nanoparticle-based drug delivery system called GAGomers. This platform was engineered to specifically target cancer cells and deliver therapeutic payloads, such as chemotherapy, RNAi, and other small-molecule drugs, directly to tumors and sites of inflammation.
Read full description
The GAGomer technology, licensed from Tel Aviv University, utilizes glycosaminoglycans (GAGs), specifically hyaluronic acid, to wrap lipid nanoparticles. This design leverages the natural affinity of GAGs for biomarkers like CD44v, which are overexpressed on certain cancer cells, to achieve targeted delivery. In January 2013, Quiet Therapeutics secured $5.5 million in a Series A funding round involving investors Pontifax, Arkin Holdings, and Gefen Biomed Investments. The funding was structured in tranches, contingent on the success of an initial feasibility study. The company also had a collaborative agreement with Roche Holding, which held the rights to one of its products. In November 2014, the scientific co-founders, Professors Margalit and Peer, received the Untold News Award for their work on the GAGomer platform. Despite its promising technology and early-stage backing, the company eventually ceased operations, with a liquidation event recorded in January 2017.
At a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Ness Ziyyona, Israel
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Oncology, DNA, Biomarkers, Genetics and genomics, Inflammatory Diseases, Drones
- Technology
- Deep Tech, Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Quiet Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2015 | $12M | $48M | Jerusalem Global Ventures | — |
| SEEDEquity / VC | Jan 2013 | $5.5M | $22M | Arkin Capital | — |
Growth signals
Latest recorded traffic for Quiet Therapeutics is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Arkin Capital
Series A1 investor entered at this stage
Jerusalem Global Ventures
Other known investors1 additional known investor
Technion Israel Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quiet Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quiet Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.